Francesco Bartoli1, Annamaria Lax2, Cristina Crocamo2, Massimo Clerici2, Giuseppe Carrà3. 1. Department of Surgery and Translational Medicine, University of Milano Bicocca, Via Cadore 48, 20900 Monza, MB, Italy. Electronic address: f.bartoli@campus.unimib.it. 2. Department of Surgery and Translational Medicine, University of Milano Bicocca, Via Cadore 48, 20900 Monza, MB, Italy. 3. Division of Psychiatry, Faculty of Brain Sciences, University College London, Charles Bell House, 67-73 Riding House Street, London W1W7EJ, UK.
Abstract
BACKGROUND: People with schizophrenia are more likely than general population to suffer from metabolic abnormalities, with second-generation antipsychotics (SGAs) increasing the risk. Low plasma adiponectin levels may lead to metabolic dysregulations but evidence in people with schizophrenia, especially for the role of SGAs, is still inconclusive. OBJECTIVE: To compare plasma adiponectin levels between people with schizophrenia and healthy controls, and to estimate the relative effect of schizophrenia and SGAs on adiponectin. METHODS: We performed a systematic review and meta-analysis of observational studies published up to 13 June 2014 in main electronic databases. Pooled standardized mean differences (SMDs) between index and control groups were generated. Appropriate subanalyses and additional subgroup analyses were carried out. RESULTS: Data from 2735 individuals, 1013 with and 1722 without schizophrenia, respectively, were analysed. Schizophrenia was not associated with lower adiponectin levels (SMD of -0.28, 95%CI: -0.59, 0.04; p=0.09). However, individuals with schizophrenia taking SGAs had plasma levels significantly lower than controls (p=0.002), which was not the case of drug free/drug naïve subjects (p=0.52). As regards single antipsychotic drugs clozapine (p<0.001) and olanzapine (p=0.04)--but not risperidone (p=0.88)--were associated with adiponectin levels lower than controls. CONCLUSIONS: People with schizophrenia per se may not have levels of adiponectin lower than controls, though treatment with SGAs is associated with this metabolic abnormality. This bears clinical significance because of hypoadiponectinemia involvement in cardiovascular diseases, even if mechanisms whereby SGAs affect adiponectin remain unexplained. Longitudinal studies evaluating long-term effects of SGAs on adiponectin are needed.
BACKGROUND:People with schizophrenia are more likely than general population to suffer from metabolic abnormalities, with second-generation antipsychotics (SGAs) increasing the risk. Low plasma adiponectin levels may lead to metabolic dysregulations but evidence in people with schizophrenia, especially for the role of SGAs, is still inconclusive. OBJECTIVE: To compare plasma adiponectin levels between people with schizophrenia and healthy controls, and to estimate the relative effect of schizophrenia and SGAs on adiponectin. METHODS: We performed a systematic review and meta-analysis of observational studies published up to 13 June 2014 in main electronic databases. Pooled standardized mean differences (SMDs) between index and control groups were generated. Appropriate subanalyses and additional subgroup analyses were carried out. RESULTS: Data from 2735 individuals, 1013 with and 1722 without schizophrenia, respectively, were analysed. Schizophrenia was not associated with lower adiponectin levels (SMD of -0.28, 95%CI: -0.59, 0.04; p=0.09). However, individuals with schizophrenia taking SGAs had plasma levels significantly lower than controls (p=0.002), which was not the case of drug free/drug naïve subjects (p=0.52). As regards single antipsychotic drugs clozapine (p<0.001) and olanzapine (p=0.04)--but not risperidone (p=0.88)--were associated with adiponectin levels lower than controls. CONCLUSIONS:People with schizophrenia per se may not have levels of adiponectin lower than controls, though treatment with SGAs is associated with this metabolic abnormality. This bears clinical significance because of hypoadiponectinemia involvement in cardiovascular diseases, even if mechanisms whereby SGAs affect adiponectin remain unexplained. Longitudinal studies evaluating long-term effects of SGAs on adiponectin are needed.
Authors: Ellen E Lee; Dorothy D Sears; Jinyuan Liu; Hua Jin; Xin M Tu; Lisa T Eyler; Dilip V Jeste Journal: J Psychiatr Res Date: 2019-06-18 Impact factor: 4.791
Authors: Brunilda Balliu; Ivan Carcamo-Orive; Michael J Gloudemans; Daniel C Nachun; Matthew G Durrant; Steven Gazal; Chong Y Park; David A Knowles; Martin Wabitsch; Thomas Quertermous; Joshua W Knowles; Stephen B Montgomery Journal: Am J Hum Genet Date: 2021-09-27 Impact factor: 11.025
Authors: Tyler R Prestwood; Roshanak Asgariroozbehani; Sally Wu; Sri Mahavir Agarwal; Ryan W Logan; Jacob S Ballon; Margaret K Hahn; Zachary Freyberg Journal: Behav Brain Res Date: 2021-01-14 Impact factor: 3.332
Authors: André F Carvalho; Marco Solmi; Marcos Sanches; Myrela O Machado; Brendon Stubbs; Olesya Ajnakina; Chelsea Sherman; Yue Ran Sun; Celina S Liu; Andre R Brunoni; Giorgio Pigato; Brisa S Fernandes; Beatrice Bortolato; Muhammad I Husain; Elena Dragioti; Joseph Firth; Theodore D Cosco; Michael Maes; Michael Berk; Krista L Lanctôt; Eduard Vieta; Diego A Pizzagalli; Lee Smith; Paolo Fusar-Poli; Paul A Kurdyak; Michele Fornaro; Jürgen Rehm; Nathan Herrmann Journal: Transl Psychiatry Date: 2020-05-18 Impact factor: 6.222